This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the Bcr–Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC . Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000; 20: 1245–1259.
Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S et al. Leflunomide-related ILD: imaging features. Modern Rheumatol, in press.
Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Esperou H et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol 2002; 20: 4271–4272.
Rosado MF, Donna E, Ahn YS . Challenging problems in advanced malignancy: case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003; 78: 3171–3173.
Ma CX, Hobday TJ, Jett JR . Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003; 78: 1578–1579.
Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004; 18: 645–646.
Isshiki I, Yamaguchi K, Okamoto S . Interstitial pneumonitis during imatinib therapy. Br J Haematol 2004; 125: 420.
Acknowledgements
We thank Drs T Suda, K Chida, R Agatsuma, T Johkoh, S Noma and Y Kurihara for evaluation of chest radiographs and CT. We also thank the following investigators who participated in this study: A Yokohama, S Iida, A Miyata, T Murayama, Y Seki, T Kozuka, Y Shiga, S Hanada, K Yoshimoto, K Hirabayashi, M Inoue, N Kakazu, S Tonai, T Yagi, KImada, Y Okutani, M Fujita, T Mamiya, H Machishi, T Denda, T Yokoyama, H Ifuku, K Hatao, KYoshinaga, Y Iizuka, H Mihara, S Matsui, Y Masuda and K Tominaga.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ohnishi, K., Sakai, F., Kudoh, S. et al. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 20, 1162–1164 (2006). https://doi.org/10.1038/sj.leu.2404207
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404207
This article is cited by
-
Wichtige Differentialdiagnosen von Lungeninfiltraten bei hämatologischen Patienten
MMW - Fortschritte der Medizin (2018)
-
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Drug Safety (2016)
-
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Current Hematologic Malignancy Reports (2016)
-
A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies
Current Hematologic Malignancy Reports (2015)
-
Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres
Medical Oncology (2014)